High-Mobility Group A2 Protein Modulates hTERT Transcription To Promote Tumorigenesis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The high-mobility group A2 gene (HMGA2) is one of the most frequently amplified genes in human cancers. However, functions of HMGA2 in tumorigenesis are not fully understood due to limited knowledge of its targets in tumor cells. Our study reveals a novel link between HMGA2 and the regulation of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, which offers critical insight into how HMGA2 contributes to tumorigenesis. The expression of HMGA2 modulates the expression of hTERT, resulting in cells with enhanced telomerase activities and increased telomere length. Treatment with suberoylanilide hydroxamide (SAHA), a histone deacetylase (HDAC) inhibitor, causes dose-dependent hTERT reporter activation, mimicking HMGA2 overexpression. By interacting with Sp1, HMGA2 interferes with the recruitment of HDAC2 to the hTERT proximal promoter, enhancing localized histone H3-K9 acetylation and thereby stimulating hTERT expression and telomerase activity. Moreover, HMGA2 knockdown by short hairpin HMGA2 in HepG2 cells leads to progressive telomere shortening and a concurrent decrease of steady-state hTERT mRNA levels, attenuating their ability to form colonies in soft agar. Importantly, HMGA2 partially replaces the function of hTERT during the tumorigenic transformation of normal human fibroblasts. These findings are potentially clinically relevant, because HMGA2 expression is reported to be upregulated in a number of human cancers as telomere maintenance is essential for tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 4×
“In contrast, the high-grade preneoplastic or cancerous cells might execute another pathway(s) to overcome the counterbalance by the OIS to stimulate proliferation or escape senescence.”
BackgroundInfluentialA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 1×
“In human cells, progressive telomere shortening eventually leads to the loss of telomere capping, resulting in recognition by a DNA damage response, the activation of p53, and the induction of cellular senescence (12, 23, 32), presumably serving as an antitumor mechanism to inhibit the progression of premalignant cell…”
BackgroundCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
Morin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495 · cited 1×
“Due to the high endogenous levels of telomerase activity found in HeLa cells (7, 42) and the high sensitivity of TRAP assays, serial dilutions of protein lysates from HeLa and HeLa/HMGA2 cells were subjected to TRAP analysis to detect their differential telomerase activity levels.”
MethodHerbig, U., Jobling, W. A., Chen, B. P. C., Chen, D. J., & Sedivy, J. M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00256-4 · Cited by 1,344
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105 · cited 1×
“33 in lung cancer is associated with the upregulation of telomerase activity in these cells (60).”
BackgroundSenescence Induced by Altered Telomere State, Not Telomere Loss
Karlseder, J., Smogorzewska, A., & de Lange, T. (2002) · Science · doi:10.1126/science.1069523 · Cited by 796
A novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation
Narita, M., Narita, M., Krizhanovsky, V., Nuñez, S., Chicas, A., Hearn, S. A., Myers, M. P., & Lowe, S. W. (2006) · Cell · doi:10.1016/j.cell.2006.05.052 · Cited by 629
Telomerase modulates expression of growth-controlling genes and enhances cell proliferation
Smith, L. L., Coller, H. A., & Roberts, J. M. (2003) · Nature Cell Biology · doi:10.1038/ncb985 · Cited by 438 · cited 2×
“For example, the expression of hTERT is involved in accelerating cell proliferation and tumor development (46, 56), enhancing cell protection from various cytotoxic stresses (35, 66) or oxidative insult (50), reducing basal cellular reactive oxygen species (ROS) levels as well as inhibiting endogenous ROS production i…”
BackgroundHug, N., & Lingner, J. (2006) · Chromosoma · doi:10.1007/s00412-006-0067-3 · Cited by 291
Oncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G., & Pisa, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203890 · Cited by 257
TERT promotes cellular and organismal survival independently of telomerase activity
Lee, J., Sung, Y. H., Cheong, C., Choi, Y. S., Jeon, H. K., Sun, W., Hahn, W. C., Ishikawa, F., & Lee, H.-W. (2008) · Oncogene · doi:10.1038/sj.onc.1211037 · Cited by 145
Yang, C., Przyborski, S., Cooke, M. J., Zhang, X., Stewart, R., Anyfantis, G., Atkinson, S. P., Saretzki, G., Armstrong, L., & Lako, M. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0677 · Cited by 136 · cited 1×
“For example, the expression of hTERT is involved in accelerating cell proliferation and tumor development (46, 56), enhancing cell protection from various cytotoxic stresses (35, 66) or oxidative insult (50), reducing basal cellular reactive oxygen species (ROS) levels as well as inhibiting endogenous ROS production i…”
BackgroundAntiadhesive Effects of GRN163L—An Oligonucleotide N3′→P5′ Thio-Phosphoramidate Targeting Telomerase
Jackson, S. R., Zhu, C.-H., Paulson, V., Watkins, L., Dikmen, Z. G., Gryaznov, S. M., Wright, W. E., & Shay, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2306 · Cited by 72
Cited by
Sp1 and the ‘hallmarks of cancer’
Beishline, K., & Azizkhan‐Clifford, J. (2015) · The FEBS Journal · doi:10.1111/febs.13148 · Cited by 524
Regulation of the human catalytic subunit of telomerase (hTERT)
Daniel, M., Peek, G. W., & Tollefsbol, T. O. (2012) · Gene · doi:10.1016/j.gene.2012.01.095 · Cited by 266
TERT promoter mutations in cancer development
Heidenreich, B., Rachakonda, P. S., Hemminki, K., & Kumar, R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.005 · Cited by 238
Oncological role of HMGA2 (Review)
Zhang, S., Mo, Q., & Wang, X. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4856 · Cited by 137
“HMGA2 knockdown in HepG2 cells results in telomere erosion, reducing the tumourigenic ability (149).”
High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression
Sgarra, R., Pegoraro, S., Ros, G., Penzo, C., Chiefari, E., Foti, D., Brunetti, A., & Manfioletti, G. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.03.001 · Cited by 77
Metadata
- Authors
- Li, A. Y.-J., Lin, H. H., Kuo, C.-Y., Shih, H.-M., Wang, C. C. C., Yen, Y., & Ann, D. K.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-07-01
- Volume
- 31
- Issue
- 13
- Pages
- 2605-2617
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2158028316
- Cited by
- 49
- References
- 16
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.